NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center

Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a three-year research collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, USA. The objective of the collaboration is to determine the potential of NeoPhore’s proprietary DNA mismatch repair inhibitor (MMRi) compounds to enhance tumour immunogenicity and induce tumour immunity.

Building on seminal discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is building a pipeline targeting novel proteins across the DNA mismatch repair ('MMR') pathway. The Company’s first-in-class MMR modulators alter the genotype of tumour cells to elicit increased tumour mutational burden, together with higher neoantigen presentation and tumour immunogenicity, which aim to reawaken the anti-tumour immune response and leverage sensitivity to immune checkpoint blockade.

Dr. Matthew Baker, Chief Executive Officer of NeoPhore, stated: “Collaborating with such prominent leaders in the field of applied cancer genetics is a great privilege. NeoPhore's therapeutic concept aims to induce neoantigen creation and cancer immunity using small-molecule inhibitors of mismatch repair, particularly in combination with other immunotherapy approaches. We look forward to the outcome of this collaboration which will ultimately advance our goal to develop next-generation immuno-oncology therapeutics.”

More news


St George’s expands successful collaboration in pursuit of new, first-in-class cancer therapies

St George’s, University of London and NeoPhore today announce the expansion of their research partnership after a successful collaboration i…


NeoPhore achieves scientific milestones

We are pleased to announce that NeoPhore recently achieved all of its investment related scientific milestones, enabling the contingent second…


Additional Series B funding announcement

We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli…

Contact us at info@neophore.com  |  
Call us +44 (0) 330 128 9990